Researchers have found that the investigational drug selumetinib shuts down the signaling of genetic mutations that prevent some patients’ thyroid cancer tumors from absorbing radioiodine, the most effective treatment for the disease.

Medical oncologist Mark Kris discusses how cancer experts are working to train IBM Watson to help assist medical professionals.

In a recent discussion as part of Memorial Sloan-Kettering’s CancerSmart lecture series, bladder cancer experts spoke about symptoms, risk factors, and the latest treatment options available.

New research suggests that analyzing genetic changes found in the bloodstream may help doctors predict which chemotherapy regimens will work for some patients.

When Dr. Patel meets with patients and their families, he walks them step-by-step through the treatment plan and ensures that they receive the most-effective surgery, when that is the best approach for the patient.

Dr. Bochner – who specializes in treating people with prostate, bladder, and kidney cancers – discusses the importance of a multidisciplinary team approach to delivering high-quality care.

A team from Memorial Sloan-Kettering has found that the makeup of immune cells in a lung tumor and in tissue surrounding a tumor can predict whether the cancer will recur after surgery.